Research programme: dry age-related macular degeneration therapies - Stuart Therapeutics
Latest Information Update: 28 May 2025
At a glance
- Originator Stuart Therapeutics
- Class Eye disorder therapies; Peptides
- Mechanism of Action Collagen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Dry age-related macular degeneration
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Dry age-related macular degeneration in USA (Ophthalmic, Drops)
- 08 Sep 2023 Stuart Therapeutics has patent protection with US PTO for compositions of matter and methods of use in a variety of anterior segment indications in ophthalmology in USA
- 09 Jan 2023 Pharmacodynamics data from a preclinical study in Diabetic macular edema released by Stuart Therapeutics